NASDAQ:RVNC • US7613301099
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for REVANCE THERAPEUTICS INC (RVNC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-01-17 | Needham | Reiterate | Hold -> Hold |
| 2024-12-23 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-12-10 | Mizuho | Maintains | Neutral -> Neutral |
| 2024-11-08 | Needham | Reiterate | Hold |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-10-28 | Needham | Reiterate | Hold |
| 2024-09-13 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2024-08-13 | Needham | Downgrade | Buy -> Hold |
| 2024-08-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-08-12 | William Blair | Downgrade | Outperform -> Market Perform |
| 2024-08-09 | Needham | Reiterate | Buy -> Buy |
| 2024-08-09 | Stifel | Maintains | Buy -> Buy |
| 2024-08-09 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-05-13 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-10 | Mizuho | Maintains | Neutral -> Neutral |
| 2024-05-10 | Needham | Maintains | Buy -> Buy |
| 2024-05-10 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-01 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-02-29 | Needham | Maintains | Buy -> Buy |
| 2024-02-29 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-02-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-01-29 | Mizuho | Downgrade | Buy -> Neutral |
| 2024-01-29 | Barclays | Maintains | Overweight -> Overweight |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 77.8M 408.50% | 132.6M 70.44% | 234.04M 76.50% | 260.43M 11.28% | 331.29M 27.21% | 423.67M 27.88% | 537.03M 26.76% | 631.94M 17.67% | 712.94M 12.82% | 807.19M 13.22% | |
| EBITDA YoY % growth | -254.85M 3.08% | -238.47M 6.43% | -209.35M 12.21% | -100.98M 51.76% | -9.18M 90.91% | 2.04M 122.22% | 110.1M 5,297.06% | 181.52M 64.87% | 274.04M 50.97% | 359.22M 31.08% | |
| EBIT YoY % growth | -274.7M -0.55% | -272.2M 0.91% | -220.725M 18.91% | -139.758M 36.68% | -77.981M 44.20% | -35.158M 54.91% | 59.257M 268.54% | 106.8M 80.23% | 152.99M 43.25% | 210.62M 37.67% | |
| Operating Margin | -353.08% | -205.28% | -94.31% | -53.66% | -23.54% | -8.30% | 11.03% | 16.90% | 21.46% | 26.09% | |
| EPS YoY % growth | -4.18 13.53% | -3.94 5.74% | -3.79 3.81% | -1.63 57.03% | -1.11 31.58% | -0.56 49.66% | 0.39 169.09% | 1.15 197.37% | 1.39 20.35% | 1.89 36.03% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.35 44.01% | -0.31 47.24% | -0.20 43.33% | -0.09 75.19% | -0.07 79.43% |
| Revenue Q2Q % growth | 77.458M 10.97% | 73.44M 41.40% | 84.558M 29.32% | 86.496M 44.45% | 92.412M 19.31% |
| EBITDA Q2Q % growth | 18.36M 143.99% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -40.8M 23.18% | N/A | N/A | N/A | N/A |
All data in USD
15 analysts have analysed RVNC and the average price target is 5.25 USD. This implies a price increase of 43.76% is expected in the next year compared to the current price of 3.65.
REVANCE THERAPEUTICS INC (RVNC) will report earnings on 2025-03-04, after the market close.
The consensus EPS estimate for the next earnings of REVANCE THERAPEUTICS INC (RVNC) is -0.35 USD and the consensus revenue estimate is 77.46M USD.
The expected long term growth rate for REVANCE THERAPEUTICS INC (RVNC) is 22.43%.